Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains

Amneal Pharmaceuticals (AMRX) is back in focus after recent trading that left the stock with a 1 day gain of 1.7% and a 7 day move of 6.0%, prompting fresh attention from investors.

See our latest analysis for Amneal Pharmaceuticals.

Zooming out, the recent 6.0% 7 day share price return comes after a modest 30 day gain of 2.9% and a 90 day share price decline of 4.6%. However, the 1 year total shareholder return of 79.9% and 3 year total shareholder return of more than 4x suggest momentum has been stronger over a longer horizon than in the last quarter.

If this kind of price action has you looking for other opportunities in healthcare related stocks, it may be a good time to check out 37 healthcare AI stocks

With Amneal reporting annual revenue of US$3.0b, net income of US$122.1m and the stock trading at US$13.17, the key question is simple: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 22.5% Undervalued

With Amneal’s fair value in the narrative set at $17.00 against the recent $13.17 close, the story centers on how its earnings engine could justify that gap.

Strategic partnerships (such as with Metsera for GLP-1s and ApiJect for U.S. injectables), expansion into high-growth categories (GLP-1s, complex injectables, and biosimilars), and the upcoming launches in international markets (particularly India and Europe) provide new avenues for incremental revenue and profit growth in the coming years.

Read the complete narrative.

Curious what sits behind that $17.00 figure? The narrative leans heavily on faster earnings growth, rising margins, and a reset profit multiple that has to carry a lot of weight.

Result: Fair Value of $17.00 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that upside story still depends on easing U.S. generics price pressure and managing high debt, and both factors could quickly weaken the fair value case.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Next Steps

With both risks and rewards on the table, does the current story feel balanced to you or tilted one way? Act while the data is fresh and review the 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If Amneal has caught your attention, do not stop here. The next strong idea could be sitting in plain sight, waiting in a focused stock list.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com